Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens

Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens

We have previously reported primary endpoints of a clinical trial testing two vaccine platforms for the delivery of Plasmodium vivax malaria DBPRII: viral vectors (ChAd63, MVA), and protein/adjuvant (PvDBPII with 50µg Matrix-M™ adjuvant). Delayed boosting was necessitated due to trial halts during t...

Full description

Bibliographic Details
Main Authors: Barrett, JR, Silk, SE, Mkindi, CG, Kwiatkowska, KM, Hou, MM, Lias, AM, Kalinga, WF, Mtaka, IM, McHugh, K, Bardelli, M, Davies, H, King, LDW, Edwards, NJ, Chauhan, VS, Mukherjee, P, Rwezaula, S, Chitnis, CE, Olotu, AI, Minassian, AM, Draper, SJ, Nielsen, CM
Format: Journal article
Language:English
Published: Frontiers Media 2024

Similar Items

Similar Items